-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38

Benzinga·11/05/2026 20:27:20
Listen to the news
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.